WARNER-LAMBERT CONSUMER HEALTH PRODUCTS U.S. PRESIDENT FOTIADES
WARNER-LAMBERT CONSUMER HEALTH PRODUCTS U.S. PRESIDENT FOTIADES will join the company Nov. 16 from Bristol-Myers Squibb, where he has been president of the company's Japanese consumer products business. George Fotiades will head the domestic division housing Warner-Lambert's OTC drug and personal care products. Fotiades also is named a corporate VP at Warner-Lambert and will be a member of the management committee, reporting to Consumer Products Sector President John Walsh. The Consumer Products Sector includes the Schick and Tetra pet care groups and the confectionery business in addition to OTCs. Fotiades succeeds Raymond LeFebvre, who left Warner-Lambert in April. LeFebvre's responsibilities had been assumed by Walsh in the interim. Among the consumer health product group's leading brands are Listerine and the recently-introduced Cool Mint Listerine mouthwashes, Rolaids antacids, Benadryl antihistamines, Halls throat lozenges, the Lubriderm skin care brand, Caladryl Lotion, Efferdent denture cleanser, e.p.t. in-home pregnancy test and Replens vaginal moisturizer. Fotiades has been with Bristol-Myers Squibb since early 1991 and moved to his current position at BMS in February of this year. Prior to that, Fotiades was senior VP and general manager for Bristol-Myers Squibb's Clairol division. He also worked at American Home Products as senior VP for the Boyle-Midway household cleaning products group and spent more than 10 years at Procter & Gamble in a variety of marketing and general management roles for P&G and its Rich-Vicks division. In an Oct. 27 press release announcing Fotiades' appointment, Warner-Lambert's Walsh said that "George possesses not only an extensive management background, but a leadership style which fosters a commitment to people and to quality. His broad consumer product experience, along with his global approach to business makes him ideally suited to help lead our U.S. OTC business."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth